At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 318 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Dulaglutide subcutaneous injection; specific dose not specified in published recordAI-extracted
Key inclusion· 4
- ✓Type 2 diabetes diagnosed ≥6 months ago
- ✓HbA1c between 7.0% and 10.0%
- ✓Stable metformin monotherapy for ≥3 months
- ✓BMI ≥25 kg/m²
Key exclusion· 7
- ✕Type 1 diabetes
- ✕Any glucose-lowering medication other than metformin within 3 months, or any prior GLP-1 receptor agonist use
- ✕History of acute MI, NYHA Class III/IV heart failure, or stroke
- ✕Active or chronic hepatitis, liver disease (except NAFLD), or ALT >2.5× upper limit of normal
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
In Brief
A Phase 2 clinical trial evaluating Dulaglutide and Placebo for Type 2 Diabetes. Completed, enrolled 318 participants across 66 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesCzechia, Mexico, Poland, Puerto Rico, Romania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJul 2017
Study CompletionAug 2017
TodayJul 2026
First PostedNov 25, 2016
Enrollment StartDec 1, 2016
Primary CompletionJul 15, 2017
Study CompletionAug 14, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.6 years ago
Interventions
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC